Trials / Not Yet Recruiting

Not Yet RecruitingNCT07264335

A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects

A Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Bioavailability and Safety of Subcutaneous SHR-1819 Injection Administered Using Different Injection Devices in Healthy Subjects

Status: Not Yet Recruiting
Phase: Phase 1
Study type: Interventional
Enrollment: 160 (estimated)

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
Sex: All
Age: 18 Years – 55 Years
Healthy volunteers: Accepted

Summary

This study is a randomized, parallel-group, open-label Phase I clinical trial designed to compare the bioavailability and safety of subcutaneous SHR-1819 injection administered via different injection devices in healthy subjects.

Conditions

Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	SHR-1819 Injection	SHR-1819 injection.

Timeline

Start date: 2025-12-01
Primary completion: 2026-03-01
Completion: 2026-03-01
First posted: 2025-12-04
Last updated: 2025-12-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07264335. Inclusion in this directory is not an endorsement.